Ari M. Vanderwalde

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Robert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio et al. · Journal of Clinical Oncology · 2015 · 2.6K citations · Full text

Medicine, Immunology, Oncology +17

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

Antoni Ribas, Reinhard Dummer, Igor Puzanov et al. · Cell · 2017 · 1.5K citations · Full text

Medicine, Immunology, Oncology +12

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

Funda Meric‐Bernstam, Herbert I. Hurwitz, Kanwal Raghav et al. · The Lancet Oncology · 2019 · 564 citations

Medicine, Oncology, Pharmacology +14

Microsatellite instability status determined by next‐generation sequencing and compared with <scp>PD</scp>‐L1 and tumor mutational burden in 11,348 patients

Ari M. Vanderwalde, David Spetzler, Nianqing Xiao et al. · Cancer Medicine · 2018 · 471 citations · Full text

Life Sciences, Oncology, Pathology +17

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma

Jason Chesney, Antoni Ribas, Georgina V. Long et al. · Journal of Clinical Oncology · 2022 · 284 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17